Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: A prospective observational study

Clinical Microbiology and Infection

Volumn 17, Issue 7, 2011, Pages 1084-1090

  Choi, W S ^a   Kim, M J ^a,c   Park, D W ^a   Son, S W ^a   Yoon, Y K ^a   Song, T ^b   Bae, S M ^b   Sohn, J W ^a   Cheong, H J ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea Centers for Disease Control and Prevention   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

Amikacin; Combination therapy; Cutaneous infection; Moxifloxacin; Mycobacterium abscessus

Indexed keywords

AMIKACIN; CLARITHROMYCIN; MOXIFLOXACIN;

ACUPUNCTURE; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; COMPARATIVE STUDY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCISION; KOREA; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ABSCESSUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN INFECTION; TREATMENT RESPONSE;

MYCOBACTERIUM ABSCESSUS;

EID: 79959939094     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03395.x     Document Type: Article

References (32)

1. Wallace RJ Jr, Silcox VA, Tsukamura M et al. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism. J Clin Microbiol 1993; 31: 3231-3239.
2. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006; 42: 1756-1763.
3. Villanueva A, Calderon RV, Vargas BA et al. Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin Infect Dis 1997; 24: 1147-1153.
4. Chadha R, Grover M, Sharma A et al. An outbreak of post-surgical wound infections due to Mycobacterium abscessus. Pediatr Surg Int 1998; 13: 406-410.
5. Ryu HJ, Kim WJ, Oh CH, Song HJ. Iatrogenic Mycobacterium abscessus infection associated with acupuncture: clinical manifestations and its treatment. Int J Dermatol 2005; 44: 846-850.
6. Song JY, Sohn JW, Jeong HW, Cheong HJ, Kim WJ, Kim MJ. An outbreak of post-acupuncture cutaneous infection due to Mycobacterium abscessus. BMC Infect Dis 2006; 6: 6.
7. Furuya EY, Paez A, Srinivasan A et al. Outbreak of Mycobacterium abscessus wound infections among "Lipotourists" from the united states who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008; 46: 1181-1188.
8. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5: 657-679.
9. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166: 405-412.
10. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998; 52: 453-490.
11. Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol 2006; 142: 1287-1292.
12. Galil K, Miller LA, Yakrus MA et al. Abscesses due to Mycobacterium abscessus linked to injection of unapproved alternative medication. Emerg Infect Dis 1999; 5: 681-687.
13. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28: 807-811.
14. Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. Fortuitum and the two subgroups of mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35: 773-775.
15. Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ III. Activities of four macrolides, including clarithromycin, against mycobacterium fortuitum, Mycobacterium chelonae, and M. Chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-184.
16. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716-746.
17. Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 21: 585-588.
18. Koh SJ, Song T, Kang YA et al. An outbreak of skin and soft tissue infection caused by Mycobacterium abscessus following acupuncture. Clin Microbiol Infect 2010; 16: 895-901.
19. Woods GL. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard M24-A. Wayne, PA: NCCLS, 2003.
20. Wikler MA, Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement [M100-S18]. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
21. Woods GL, Bergmann JS, Witebsky FG et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 1999; 37: 1676-1682.
22. Hector JS, Pang Y, Mazurek GH, Zhang Y, Brown BA, Wallace RJ Jr. Large restriction fragment patterns of genomic mycobacterium fortuitum DNA as strain-specific markers and their use in epidemiologic investigation of four nosocomial outbreaks. J Clin Microbiol 1992; 30: 1250-1255.
23. Wallace RJ Jr, Zhang Y, Brown BA, Fraser V, Mazurek GH, Maloney S. DNA large restriction fragment patterns of sporadic and epidemic nosocomial strains of Mycobacterium chelonae and Mycobacterium abscessus. J Clin Microbiol 1993; 31: 2697-2701.
24. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001; 43: 163-168.
25. Wallace RJ Jr, Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-1681.
26. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-1376.
27. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ats/idsa statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
28. Diagnosis treatment of disease caused by nontuberculous mycobacteria. This official statement of the american thoracic society was approved by the board of directors, March 1997. Medical section of the american lung association. Am J Respir Crit Care Med 1997; 156: S1-S25.
29. Jeon K, Kwon OJ, Lee NY et al. Antibiotic treatment of mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896-902.
30. Wallace RJ Jr, Bedsole G, Sumter G et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34: 65-70.
31. Park S, Kim S, Park EM et al. In vitro antimicrobial susceptibility of mycobacterium abscessus in korea. J Korean Med Sci 2008; 23: 49-52.
32. Cremades R, Santos A, Rodriguez JC et al. Screening for sterilizing activity of antibiotic combinations in an acid model of rapidly growing mycobacteria during the stationary phase of growth. Chemotherapy 2009; 55: 114-118.